Pancreatic ductal adenocarcinoma
(PDAC) is an aggressive malignancy associated with <5% 5-year survival, in
which standard chemotherapeutics have limited benefit. The disease is
associated with significant intra- and peritumoral inflammation and failure of
protective immunosurveillance. Indeed, inflammatory signals are implicated in
both tumour initiation and tumour progression. The major pathways regulating
PDAC-associated inflammation are now being explored. Activation of leukocytes,
and upregulation of cytokine and chemokine signalling pathways, both have been
shown to modulate PDAC progression. Therefore, targeting inflammatory pathways
may be of benefit as part of a multi-target approach to PDAC therapy. This
review explores the pathways known to modulate inflammation at different stages
of tumour development, drawing conclusions on their potential as therapeutic
targets in PDAC.
Source: Exploiting inflammation for
therapeutic gain in pancreatic cancer. Steele CW, Jamieson NB, Evans TR, McKay
CJ, Sansom OJ, Morton JP, Carter CR (rosscarterno1@gmail.com).
Br J Cancer. 2013 Feb 5.
Free paper available at:
Aucun commentaire:
Enregistrer un commentaire